CollPlant Biotechnologies (NASDAQ:CLGN) Stock Rating Reaffirmed by HC WainwrightZolmax • 12 days ago
CollPlant Biotechnologies (NASDAQ:CLGN - Get Free Report)s stock had its "buy" rating reiterated by HC Wainwright in a research report issued on Friday, Benzinga reports. They presently have a...
Share to Feed
Despite a net loss, CollPlant reports substantial revenue increase and progress in key partnerships, setting a resilient course for 2024.Related Stocks: CLGN...
Related Stocks: NAS:CLGN...
CollPlant Biotechnologies Ltd. (CLGN) has released an update. CollPlant Biotechnologies Ltd. reports a successful 2023 with key advancements in the...
COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE PR...
CollPlant Biotechnologies GAAP EPS of -$0.62, revenue of $10.96M...
COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE PR...
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FULL YEAR FINANCIAL RESULTS AND...
CollPlant Biotechnologies (NASDAQ:CLGN Get Free Report) and Milestone Scientific (NYSE:MLSS Get Free Report) are both small-cap medical companies, but which is the better investment...
CollPlant Issues Letter to Shareholders CollPlant Issues Letter to Shareholders PR Newswire REHOVOT, Israel, Feb. 15, 2024 REHOVOT, Israel, Feb. 15, 2024 /PRNewswire/ -- CollPlant Biotechnologies...